MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: General Electric Company
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GE Healthcare’s Biosafe Announces Sefia Platform to Address Multiple Steps in Cell Therapy Production Process - GE Healthcare’s recently acquired Biosafe Group introduces Sefia - Biosafe.ch / GEHealthcare.com
GE Healthcare’s Biosafe Announces Sefia Platform to Address Multiple Steps in Cell Therapy Production Process

 

NewswireToday - /newswire/ - Chalfont St. Giles, United Kingdom, 2016/09/30 - GE Healthcare’s recently acquired Biosafe Group introduces Sefia - Biosafe.ch / GEHealthcare.com. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

At the International Society for Cellular Therapy’s Regional Meeting in Memphis, TN, GE Healthcare’s recently acquired Biosafe Group introduces Sefia, a state-of-the-art, multi-function platform which uses a combination of continuous-flow centrifugation, temperature control and fluidic management to enable purification, concentration, washing and final formulation during cell processing. Combined with GE Healthcare’s existing portfolio, Sefia further advances access to a single-solution manufacturing platform to enable turnkey, scalable manufacturing of cell therapies.

Sefia is a functionally-closed laboratory instrument, CE certified for safety compliance with IEC 61010, IEC 61 326, and IEC 62304 standards, and designed for use in good automated manufacturing practice (GAMP)-compliant environments. Harnessing two new technologies along with smart process control, temperature regulation and eight separate fluid pathways Sefia performs simple and complex manipulation of large volumes of cells at a fast processing speed. Sefia features:

The ‘CT 800.1’ kit, with the ‘A-800’ continuous flow separation chamber (allowing for processing of large volumes of cellular products at a flow rate up to 10 litres per hour).

‘FlexCell’, the first of several forthcoming protocols designed for specific cell therapy applications. The FlexCell protocol and kit will be dedicated to large-volume washing of cells in the production of CAR-T therapies.

The Sefia platform builds on Biosafe’s experience in the cell therapy and regenerative medicine market with its Sepax™ and Smart-Max machines. Integrating Biosafe’s products into GE’s portfolio of tools, technologies, and services brings the industry closer to a complete ecosystem that supports the industrialization of this emerging class of medicine.

Sefia offers:

• FlexCell protocol;
• The ‘CT 800.1’ kit, including the ‘A-800’ continuous flow separation chamber;
• Versatile applications serving preparation, isolation, washing, concentration and final formulation steps of a cell therapy process;
• Combinable protocols, temperature regulation and smart process control;
• A closed and sensor controlled system;
• Full process traceability with GMP compliance;
• Flexibility of production with up to eight separate fluid pathways;
• Intuitive user guidance.

​About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.

About GE Healthcare Life Sciences
GE Healthcare's $4B Life Sciences business is on a mission to accelerate an age of molecular and precision medicine by providing expertise, tools and solutions for a wide range of applications, including basic research of cells and proteins, drug discovery, cell therapy and regenerative medicine, as well as tools and technology to support large-scale manufacturing of biopharmaceuticals, vaccines and biologics such as insulin. It also supplies leading contrast, PET and nuclear medicine agents for diagnostic imaging to help doctors make more informed diagnoses for better patient outcomes. The company's mission is to help enable a new era of molecular and precision medicine by providing customers with the tools, insight and knowledge to guide them ever more quickly from better biological understanding to better clinical therapies.

GE Healthcare Life Sciences acquired the Biosafe Group in July 2016. Biosafe (biosafe.ch) is active in the design, manufacture and marketing of automated cell processing systems.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services / Equipment articles,
CATCH Visitors via Your Competitors Announcements!


GE Healthcare’s Biosafe Announces Sefia Platform to Address Multiple Steps in Cell Therapy Production Process

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Erin Bryant - GE Healthcare 
203-450-5326 erin.bryant[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Medical Services / Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Medical Services / Equipment Most Recent Related Newswires:

Bruker Introduces Updated B.I.QUANT-UR™ Module for Fully Validated Metabolite Quantification in Urine Using NMR
SCHOTT Extends SyriQ BioPure® Syringe Format to Enable Optimized Administration
Hand Hygiene Market Will Reach .98 Billion in the US and EU5 with High Adoption of Gamification Finds Frost & Sullivan
Rise in Pharmaceutical Applications to Foster Demand for Mass Spectrometers in Europe Finds Frost & Sullivan
Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio™
Withings Launches ScanWatch - the First Hybrid Smartwatch to Combine Medical Grade Electrocardiogram and Sleep Apnea Detection
Bruker Introduces Dedicated Light-Sheet Microscope for Highly Multiplexed 3D Cell Culture Live Imaging
Inkwood Research Publishes Global 3D Cell Culture Market Forecast 2019-2027
Bruker’s PeakForce Tapping is Fastest Growing AFM Mode
Philips Commended by Frost & Sullivan for Advancing Access to Affordable, High-quality Care through Its Incisive CT Platform
ZOLL to Showcase Portfolio of Advanced Resuscitation Technologies for the Workplace At A+A Congress 2019
Bruker Launches Ultrafast FTIR Imaging Microscope LUMOS II
Drug Delivery Devices Offering Enhanced Connectivity to Find Higher Uptake Among Hospitals finds Frost & Sullivan
Global Inorganic Scintillators Market Projected to Grow At 5.28% CAGR Through 2027 Reports Inkwood Research
Rising Aging Population Projects the Global Hearing Aids Market At 5.42% CAGR by 2027 Reports Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)